Liver cancer cases are projected to double, but more than half could be preventable
Liver cancer is the sixth most common cancer in the world, with around 870,000 cases in 2022. That's projected to increase to 1.52 million cases in 2050, the new report found, if no changes are made.
The leading cause of liver cancer is viral infections, including the hepatitis B and C viruses. Hepatitis B infections — which are preventable with a vaccine — accounted for 39% of liver cancers in 2022. That's expected to fall slightly, to 36.9%, by 2025. Hepatitis C accounted for 29.1% of liver cancers in 2022 and is also projected to fall, to 25.9%, by 2050.
The proportions of alcohol- and obesity-related liver cancers, however, are projected to rise in the next 25 years. Alcohol accounted for 18.8% of liver cancers in 2022, and that is expected to increase to 21.1% in 2050. The share of liver cancers caused by obesity-related disease is projected to increase from 8% to 10.8% by 2050 due to increasing rates of obesity, diabetes and high cholesterol and other metabolic risk factors.
Dr. Hashem El-Serag, one of the report's co-authors and chair of the department of medicine at the Baylor College of Medicine in Houston, said the public usually thinks of alcohol as the biggest risk factor for liver cancer.
'I think for most people, if you say cirrhosis, they immediately think of a relative, of someone who was a heavy drinker,' El-Serag said. 'I think the vast majority do not make the tie between MASLD, or fatty liver, and cirrhosis and liver cancer.'
MASLD, or metabolic dysfunction-associated steatotic liver disease, affects about 25% of adults in the U.S. It's caused by a buildup of fat in the liver. About 5% of U.S. adults have a more severe form, called metabolic dysfunction-associated steatohepatitis (MASH), which can lead to scarring, or cirrhosis, of the liver, significantly increasing the risk of cancer.
Excess alcohol consumption can also lead to cirrhosis.
Liver cancer is still relatively rare in the United States, representing 2.1% of all new cancer diagnoses in 2025. The report estimated that by 2040, U.S. rates of MASLD could more than double, affecting more than 55% of adults.
Detecting liver cancer risk factors
Earlier detection and effective treatment plans for MASLD can reduce the risk of obesity-related liver cancer, El-Serag said. The most common treatment is weight loss. GLP-1 weight loss drugs, which include Ozempic and Wegovy, are promising, he said. (A clinical trial published in April found that Wegovy treated MASH in about two-thirds of patients.)
However, people aren't screened for MASLD like they are for viral hepatitis, El-Serag said.
Dr. Arun Jesudian, a hepatologist and the director of liver quality and inpatient liver services at Weill Cornell Medicine and NewYork-Presbyterian, said patients are tested for MASLD and/or MASH if they have elevated liver enzymes in their blood.
Raising awareness about MASLD among both patients and doctors can lead to more effective testing and diagnosis, Jesudian said.
'I think then we need to make sure that providers who are interacting with these patients are looking at the liver disease component of metabolic syndrome,' he said, referring to patients with a cluster of conditions including high blood sugar, high blood pressure and excess weight. 'So checking liver enzymes, that they know how to assess for fibrosis, even based on these blood test scores.'
MASLD and MASH can often be asymptomatic, making self-detection more challenging.
'Right now, it's haphazard. Some people get tested. Others get suspected. Third, who knows?' El-Serag said.
Dr. Neehar Parikh, a hepatologist at the University of Michigan who specializes in liver cancer, said he is seeing more patients with MASLD as a driving factor for liver cancer.
Patients with MASLD can develop liver cancer without developing cirrhosis, making it even more challenging to detect those cases, Parikh said. Up to 40% of those with liver cancers linked to MASLD don't develop cirrhosis, according to the report.
Figuring out who those patients are is the 'million-dollar question,' he said. 'Those patients that develop MASLD that develop liver cancer, you know, how do you screen that population? We don't really know what to do.'
Still, Parikh said these types of cases are rare.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
How will Trump's E.U. tariffs affect drug prices?
President Donald Trump's trade deal with the European Union may lead to higher prices for brand-name drugs in the United States, including blockbuster medications like Ozempic and Wegovy, experts say. The trade deal, announced Sunday, places a 15% tariff on most imported goods from the E.U., including pharmaceuticals. While that comes in well below the 200% tariffs Trump had threatened on pharmaceutical imports earlier this month, it'll still have an impact. Pharmaceuticals are the United States' fifth largest import, said Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School. Europe is a major manufacturing hub for brand-name drugs in particular. Nearly half of the active ingredients for brand-name drugs taken in the United States are produced in European countries such as Ireland, Germany, Italy and Belgium, Kesselheim said. Europe is also where many drugmakers do final steps, such as filling and packaging. Novo Nordisk's diabetes and obesity drugs Ozempic and Wegovy are both produced in Denmark. Botox, made by Allergen, and the cancer drug Keytruda from drugmaker Merck are made in Ireland. (In recent years, however, more of Keytruda's manufacturing has shifted to the United States.) While brand-name drugs only account for about 10% of prescriptions filled in the United States, they make up about 80% of all drug spending, Kesselheim said. 'That's because they're priced so high,' he said. 'Each individual [generic] statin is pennies, whereas Botox is thousands to tens of thousands of dollars.' In the short term, drug companies might increase the list prices of these products to account for the higher cost, said Rena Conti, an associate professor at Boston University's Questrom School of Business. 'U.S. consumers will pay more at the pharmacy counter for these drugs,' Conti said. 'What patients pay at the pharmacy counter reflects drug companies' set price list.' Kesselheim said it's an open question whether patients would even notice the higher prices, given that brand-name drugs are already so expensive. 'The drug prices are already two to three times higher in the United States than they are in other countries,' he said. 'There is a lot more room for drug companies [to charge more.]' Generic drugs, on the other hand, are often sold at close to the cost that they're made. About 9 out of 10 prescription drugs taken in the United States are generics, Kesselheim added. The Pharmaceutical Research and Manufacturers of America, a drug industry trade group, did not immediately respond to a request for comment. The E.U. tariffs aren't expected to affect the prices of many generic drugs. Some generic drugs are made in Europe, but the majority are manufactured in countries like China and India, said Arthur Caplan, the head of the division of medical ethics at NYU Langone Medical Center in New York City. There have been concerns that tariffs on these countries could drive up the cost of generic drugs and exacerbate drug shortages. Generic drugs aren't a lucrative enough business for companies to invest in new manufacturing facilities in the United States, Caplan said. A spokesperson for the Association for Accessible Medicines, a trade group that represents generic drugmakers, said the group is still assessing the potential impact of the tariffs as well as the specifics of the trade deal. This article was originally published on Se produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información
Yahoo
3 hours ago
- Yahoo
Novo Nordisk Shares Plunge, Drag Down Weight-Loss-Drug ETFs
Shares of Danish pharmaceutical giant Novo Nordisk A/S (NVO) tumbled 22% Tuesday after the company slashed its 2025 outlook and announced a CEO change, sending shockwaves through a range of ETFs tied to weight-loss drugs. Novo, best known for pioneering GLP-1 drugs like Ozempic and Wegovy, now expects sales to grow 8% to 14% this year, down from a prior range of 13% to 21%. Operating profit guidance was similarly lowered to 10% to 16% from a previous estimate of 16% to 24%. Invest in Gold American Hartford Gold: #1 Precious Metals Dealer in the Nation Priority Gold: Up to $15k in Free Silver + Zero Account Fees on Qualifying Purchase Thor Metals Group: Best Overall Gold IRA The stock is now down 66% from its mid-2024 highs, erasing hundreds of billions in market cap and pressuring several ETFs with heavy exposure to the once high-flying name. Novo is the top holding in the Roundhill GLP-1 & Weight Loss ETF (OZEM), with a 17% weighting. It also makes up 11% of the Amplify Weight Loss Drug & Treatment ETF (THNR) and 8% of the VanEck Pharmaceutical ETF (PPH). A leveraged ETF tied directly to the stock, the Defiance Daily Target 2X Long NVO ETF (NVOX), fell more than 40% on the day. Novo Decline Impacts OZEM, Weight-Loss ETFs Thematic ETFs tied to the GLP-1 boom have been hit hard by Novo's collapse. OZEM fell more than 5% on Tuesday, while THNR dropped 3%. Traditional pharma ETFs like PPH also declined, though to a lesser extent. The leveraged NVOX ETF posted one of the steepest declines in the entire ETF universe. For a full list of ETFs that hold Novo Nordisk, check out Novo Nordisk stock page. Compounding Problems In a press release, Novo Nordisk attributed the lowered guidance in part to persistent use of compounded GLP-1 drugs—custom-made knockoffs that some clinics continue to sell even after the FDA ended its temporary allowance for such practices in May. 'Despite the expiry of the FDA grace period for mass compounding on 22 May 2025, unsafe and unlawful mass compounding has continued,' the company said. 'Multiple entities continue to market and sell compounded GLP-1s under the false guise of 'personalisation' ... exposing patients to the significant risks posed by knockoff 'semaglutide' drugs made with illicit or inauthentic foreign active pharmaceutical ingredients.' Novo has launched litigation and is calling on regulators to crack down more aggressively, but the damage is already being felt. The easy availability of cheaper compounded alternatives is undercutting demand for Wegovy and Ozempic, especially in the U.S., where insurers remain reluctant to cover the pricey branded versions. NVO Falling Behind LLY At the same time, Novo is also facing growing competitive pressure from Eli Lilly and Co. (LLY), which has seen blockbuster success with its GLP-1 drug Zepbound. Some studies suggest Zepbound may be more effective than Wegovy, giving Lilly the edge both clinically and commercially. Adding to the uncertainty, Novo also announced that Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen as CEO. Doustdar previously led international operations and will now be tasked with navigating one of the most turbulent periods in the company's recent | © Copyright 2025 All rights reserved
Yahoo
3 hours ago
- Yahoo
Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?
Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and regulatory, that have led investors to bet against the company. The company reported disappointing data from two late-stage studies for its next-generation subcutaneous obesity candidate, CagriSema, a follow-up drug to Wegovy. In these studies, CagriSema demonstrated a lower-than-expected reduction in body weight, despite meeting the primary endpoints. Earlier, Medicare announced that it will not cover costly weight-loss drugs, including NVO's Wegovy (semaglutide), as obesity remains unclassified as a disease. Consequently, these medications, often viewed as cosmetic, may become less accessible to patients. Novo Nordisk is also currently facing a major transition in its executive management as CEO Lars Fruergaard Jørgensen will step down due to market headwinds and a decline in the company's stock since mid-2024. The search for his successor is currently underway. Moreover, Novo Nordisk faces intense competition from its arch-rival Eli Lilly LLY in the diabetes and obesity care market. LLY markets its tirzepatide injections as Mounjaro for type II diabetes (T2D) and Zepbound for obesity. Despite being on the market for less than three years, Lilly's Mounjaro and Zepbound have witnessed strong sales driven by rapid demand. Zepbound had earlier outperformed Novo Nordisk's Wegovy (20.2% compared with 13.7%, respectively) in a weight-loss head-to-head study. This could lead to a shift in patient preference from Wegovy to Zepbound, potentially resulting in a loss of market share. Lilly has also been taking significant strides in the development of oral therapies for obesity, effectively putting pressure on Novo Nordisk. In April 2025, LLY reported first phase III success for its oral GLP-1 candidate, orforglipron, in lowering blood glucose and promoting weight loss in T2D patients. Oral pills could boost adherence over injections. Additionally, NVO recently ended its collaboration agreement with Hims & Hers Health, which will temporarily hurt its objective of increasing Wegovy's patient access, resulting in a slowdown in obesity market share gain. However, not all is wrong at NVO. Novo Nordisk is making good progress with its pipeline, which includes several other new candidates for T2D and obesity. The company also has strong fundamentals, and the untapped nature of the obesity market makes us believe that the setback is temporary. Let's dig deeper and understand the company's strengths and weaknesses to understand how to play the stock after the recent price drop. Semaglutide - NVO's Growth Engine Novo Nordisk's success in recent years has been driven by its popular semaglutide-based GLP-1 products — Ozempic (injection) and Rybelsus (oral) for T2D, and Wegovy for obesity. The company holds a strong position in diabetes care, with one of the industry's broadest portfolios and a global diabetes market share of 33.3% as of March 2025, led by Rybelsus, Ozempic, and Victoza. It also dominates the GLP-1 segment with a 54% global market share. Wegovy is a major revenue driver, with first-quarter 2025 sales up 83% to DKK 17.4 billion on strong prescription growth. Ozempic also continues to boost overall revenues. To protect its lead amid competition from Lilly, Novo Nordisk is heavily investing in its GLP-1 manufacturing capacity. As of July 1, CVS Caremark, a major pharmacy benefit manager, has designated Wegovy as its preferred GLP-1 therapy for weight loss. Novo Nordisk is expanding semaglutide's reach through new indications. Wegovy is now approved for reducing major cardiovascular events, easing HFpEF symptoms, and relieving osteoarthritis-related knee pain in obesity. Ozempic's label includes use in T2D patients with cardiovascular and kidney disease. The FDA is reviewing Novo Nordisk's application for a 25 mg oral semaglutide for obesity, with a decision expected by year-end. NVO has also filed Rybelsus for cardiac event prevention in T2D and is studying semaglutide for liver disease. A 7.2 mg Wegovy dose, showing up to 25% weight loss in the STEP UP study, is under EU review. Label expansion is also being sought for Ozempic in treating peripheral artery disease in the United States and the EU. Beyond GLP-1s, Novo Nordisk is expanding into rare diseases, with regulatory plans for Mim8 (hemophilia A) and EU approval of Alhemo (hemophilia A/B with inhibitors). It also expects to file for semaglutide in metabolic dysfunction–associated steatohepatitis in both the United States and the EU in 2025. NVO Focuses on Next-Generation Drugs for Obesity Novo Nordisk is also developing several next-generation obesity candidates in its pipeline, especially targeting the lucrative U.S. market. The most advanced weight loss candidate in Novo Nordisk's pipeline is CagriSema, a fixed-dose combination of a long-acting amylin analogue and Wegovy. The company is already planning its regulatory submission in 2026. Novo Nordisk is also developing a small-molecule oral CB1 inverse agonist, monlunabant, in a mid-stage study. The company is currently gearing up to advance Amycretin, an investigational unimolecular GLP-1 and amylin receptor agonist, for weight management into late-stage development. The phase III program on amycretin is planned to be initiated during the first quarter of 2026. Recently, Novo Nordisk signed a $2.2 billion deal with Septerna for developing and commercializing oral small-molecule medicines for treating obesity, T2D and other cardiometabolic diseases. Competition Heating Up in the Obesity Space Competition in the obesity market is heating up as the obesity market is expected to expand to $100 billion by 2030, according to data from Goldman Sachs. Lilly and Novo Nordisk presently dominate the market. Several other companies like Amgen AMGN and Viking Therapeutics VKTX are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline. Amgen has begun a broad phase III program on its dual GIPR/GLP-1 receptor agonist, MariTide, across obesity, obesity-related conditions and T2D, with the first two phase III studies initiated in March. Viking Therapeutics' dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity. Viking Therapeutics recently launched the late-stage VANQUISH program for subcutaneous VK2735 in obesity and T2D, following the initiation of the mid-stage VENTURE study on the oral version earlier this year. NVO's Stock Price, Valuation, Estimates In the past year, Novo Nordisk shares have lost 51.1% compared with the industry's 17% decline. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below. The stock is currently trading below its 50 and 200-day moving averages. NVO Stock Underperforms the Industry, Sector & the S&P 500 Image Source: Zacks Investment Research Novo Nordisk is trading at a premium to the industry, as seen in the chart below. Going by the price/earnings ratio, the company's shares currently trade at 16 forward earnings, which is higher than 15.12 for the industry. However, the stock is trading much below its five-year mean of 29.25. NVO Stock Valuation Image Source: Zacks Investment Research Earnings estimates for 2025 have improved from $3.85 to $3.98 per share over the past 60 days. During the same time frame, Novo Nordisk's 2026 earnings per share estimates have declined from $4.65 to $4.59. NVO Estimate Movement Image Source: Zacks Investment Research The stock's return on equity on a trailing 12-month basis is 80.95%, which is higher than 33.55% for the large drugmaker industry, as seen in the chart below. NVO Return on Equity Image Source: Zacks Investment Research Here's How to Play NVO Stock Novo Nordisk, currently carrying a Zacks Rank #3 (Hold), has the potential to boost shareholders' wealth in the future. Despite past pipeline and regulatory setbacks, along with the ongoing transition in leadership, we remain confident that NVO is a good stock to retain. The company operates in a lucrative market that is rapidly expanding. Its strong year-over-year revenues and profits, fueled by rising demand for Wegovy and Ozempic, suggest long-term potential. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The company is actively working to expand the approved uses of its key semaglutide products, Wegovy, Ozempic, and Rybelsus, which could significantly increase the eligible patient pool and drive future revenues. However, Eli Lilly remains a formidable adversary in the obesity market space, which threatens NVO's market share. Hence, we can conclude that investors currently holding the NVO stock should not get spooked by the recent downtrend in the stock price. In fact, new Investors can use the current dip in the price to acquire the stock to enjoy significant value creation in the long run. Short-term investors are, however, advised to steer clear of the stock to avoid near-term volatility. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
